An update on the CNS manifestations of neurofibromatosis type 2.

Clicks: 454
ID: 58742
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #3 of 438 articles by views in acta neuropathologica

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 438 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Neurofibromatosis type II (NF2) is a tumor predisposition syndrome characterized by the development of distinctive nervous system lesions. NF2 results from loss-of-function alterations in the NF2 gene on chromosome 22, with resultant dysfunction of its protein product merlin. NF2 is most commonly associated with the development of bilateral vestibular schwannomas; however, patients also have a predisposition to development of other tumors including meningiomas, ependymomas, and peripheral, spinal, and cranial nerve schwannomas. Patients may also develop other characteristic manifestations such as ocular lesions, neuropathies, meningioangiomatosis, and glial hamartia. NF2 has a highly variable clinical course, with some patients exhibiting a severe phenotype and development of multiple tumors at an early age, while others may be nearly asymptomatic throughout their lifetime. Despite the high morbidity associated with NF2 in severe cases, management of NF2-associated lesions primarily consists of surgical resection and treatment of symptoms, and there are currently no FDA-approved systemic therapies that address the underlying biology of the syndrome. Refinements to the diagnostic criteria of NF2 have been proposed over time due to increasing understanding of clinical and molecular data. Large-population studies have demonstrated that some features such as the development of gliomas and neurofibromas, currently included as diagnostic criteria, may require further clarification and modification. Meanwhile, burgeoning insights into the molecular biology of NF2 have shed light on the etiology and highly variable severity of the disease and suggested numerous putative molecular targets for therapeutic intervention. Here, we review the clinicopathologic features of NF2, current understanding of the molecular biology of NF2, particularly with regard to central nervous system lesions, ongoing therapeutic studies, and avenues for further research.
Reference Key
coy2019anacta Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Coy, Shannon;Rashid, Rumana;Stemmer-Rachamimov, Anat;Santagata, Sandro;
Journal acta neuropathologica
Year 2019
DOI
10.1007/s00401-019-02029-5
URL
Keywords
glioma meningioma smarcb1 vestibular schwannoma acoustic neuroma cellular schwannoma central neurofibromatosis erm (ezrin/radixin/moesin) family scaffolding ependymoma epidemiology of familial tumor syndromes gardner glial hamartia glial micro-hamartoma intraneural schwannoma lztr1 manchester (nih) criteria manchester criteria meningioangiomatosis merlin nf2 neurofibroma neurofibromatosis type 2 neurofibromatosis type ii neurofibromin 2 plexiform schwannoma posterior subcapsular lenticular opacities sh3pxd2a-htra1 smarce1 sufu schwannoma schwannomatosis schwannomin verocay body von recklinghausen wishart

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.